Determination of Regulatory Review Period for Purposes of Patent Extension; AMTAGVI

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AMTAGVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

Tags

information blocking, Notice, Health and Human Services Department, Food and Drug Administration

Related exam domains

None matched

Source record id

2026-02974

First seen by InfoSec Signals

9/23/2026

Exam domain labels come from a keyword heuristic and are study hints, not an official mapping. The summary is the publisher's own text, shortened; the linked record is authoritative.